ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler
  
ASCO 2025 Meeting
ASCO 2025 Meeting (Alaric DeArment)

More from ASCO

More from Therapy Areas